|
Upcoming HSCI Events
|
Harvard Medical School
Thursday, Jan 28
4:30 - 6:00 PM
Dana-Farber Cancer Institute
Tuesday, March 29
8:00 AM - 6:00 PM
Harvard University
Thursday, May 19
8:00 AM - 6:15 PM
Harvard Business School
July 11 - 13
Look for registration to open in March.
|
|
Funding Opportunities
| |
Postdoctoral and professional positions are available in the following HSCI and HSCI-affiliated labs:
Karp Lab at Brigham and Women's Hospital
Shah Lab at Massachusetts General Hospital and Harvard Medical School
The following opportunities are available to postdocs:
Application deadline:
January 29, 2016
The following opportunities are available to HSCI faculty:
Application deadline:
January 31, 2016
|
|
HIP Mentorship
| |
If you would like to be a HSCI
Internship Program (HIP) Mentor this summer, please apply here.
Application deadline:
Friday, Feb 26, 2016
|
|
People News
| |
Donald Ingber, MD, PhD, from Wyss Institute, joins HSCI as Affiliate Faculty.
Jennifer Lewis, ScD, from Harvard University, joins HSCI as Affiliate Faculty.
Ana Paula Abreu Metzger, MD, PhD, from Brigham and Women's Hospital, joins HSCI as Affiliate Faculty.
Brian J. Wilson, PhD, from , joins HSCI as Affiliate Faculty
If you would like to share your achievements, awards, or research with the HSCI community, please email hannah_robbins@harvard.edu
|
|
|
HSCI Seed Grants 2016
The Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its 2016 cycle.
The purpose of this program is to provide early funding for innovative projects in the field of stem cell & regenerative biology. While proposals at all stages of development are welcome, this year the HSCI strongly encourages proposals with either a translational or clinical focus. This seed grant cycle, the HSCI intends to award up to ten grants, contingent upon the number and quality of the applications received, as well as the availability of HSCI funds.
In determining whether a proposal falls into the translational/clinical science (as opposed to basic science) category, please consider the focus of your proposal. In general, translational/clinical proposals are those which aim at:
- Producing new therapies and/or therapeutic products (e.g. cellular products, large/small molecules, biomaterials, etc.), or
- Discovering the mechanisms, pathways, or models underlying such therapies/therapeutic products, or
- Manufacturing and testing stem cell-based therapies using studies designed to fulfill all applicable institutional, state, and federal regulatory requirements.
Any seed grants awarded during this cycle will be funded at up to $50,000 in total costs (including indirect costs, maximum 20% of total direct costs-basis) per year, for a period not to exceed two years.
Basic-science proposals will not be reviewed separately from those with a translational/clinical focus. All proposals will be reviewed by the HSCI Executive Committee.
The HSCI reserves the right to not award any seed grants this application cycle.
APPLICATION DUE DATE: Sunday, January 31st, 2016
For more information regarding eligibility criteria, the application and submission process, and the review criteria, please view the call for proposals on our HSCI website here.
|
|
Research and Reviews
- Rubin Lab: A summary of the current challenges for creating meaningful patient-specific in vitro models to study brain disorders discussed at the four-day Banbury meeting in April 2015. (Stem Cell Reports meeting report).
- Sankaran, Musunuru, and Zon labs: Combining human genome variation studies with genome editing approaches has the potential to improve cell and tissue production for regenerative medicine. (Cell Stem Cell report)
- Silberstein Lab: Detailed mapping of conventional cDNA annotated serologically defined red blood cell and serologically defined platelet alleles can enable accurate prediction of RBC and PLT antigens from whole genomic sequencing data. (Transfusion paper)
|
|
Student Spotlight
Matrix spoke to Olivia Weeks, a graduate student in Wolfram Goessling's lab at Brigham and Women's Hospital and Dana-Farber Caner institute.
Olivia Weeks has been selected by HSCI to receive the 2015 Sternlicht Director's Fund Fellowship. The Fund was established in 2007 and has supported the educational pursuits of nine graduate students and two postdoctoral fellows participating in type 1 diabetes researcher at Harvard University. Read more about Olivia and her work here.
|
|
|
|
|
